Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia
- PMID: 16100246
- DOI: 10.1152/ajpheart.00599.2005
Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia
Abstract
The rate of cardiac fatty acid oxidation is regulated by the activity of carnitine palmitoyltransferase-I (CPT-I), which is inhibited by malonyl-CoA. We tested the hypothesis that the activity of the enzyme responsible for malonyl-CoA degradation, malonyl-CoA decarboxlyase (MCD), regulates myocardial malonyl-CoA content and the rate of fatty acid oxidation during demand-induced ischemia in vivo. The myocardial content of malonyl-CoA was increased in anesthetized pigs using a specific inhibitor of MCD (CBM-301106), which we hypothesized would result in inhibition of CPT-I, reduction in fatty acid oxidation, a reciprocal activation of glucose oxidation, and diminished lactate production during demand-induced ischemia. Under normal-flow conditions, treatment with the MCD inhibitor significantly reduced oxidation of exogenous fatty acids by 82%, shifted the relationship between arterial fatty acids and fatty acid oxidation downward, and increased glucose oxidation by 50%. Ischemia was induced by a 20% flow reduction and beta-adrenergic stimulation, which resulted in myocardial lactate production. During ischemia MCD inhibition elevated malonyl-CoA content fourfold, reduced free fatty acid oxidation rate by 87%, and resulted in a 50% decrease in lactate production. Moreover, fatty acid oxidation during ischemia was inversely related to the tissue malonyl-CoA content (r = -0.63). There were no differences between groups in myocardial ATP content, the activity of pyruvate dehydrogenase, or myocardial contractile function during ischemia. Thus modulation of MCD activity is an effective means of regulating myocardial fatty acid oxidation under normal and ischemic conditions and reducing lactate production during demand-induced ischemia.
Similar articles
-
Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation.Circ Res. 2004 May 14;94(9):e78-84. doi: 10.1161/01.RES.0000129255.19569.8f. Epub 2004 Apr 22. Circ Res. 2004. PMID: 15105298
-
Malonyl-CoA decarboxylase inhibition as a novel approach to treat ischemic heart disease.Cardiovasc Drugs Ther. 2006 Dec;20(6):433-9. doi: 10.1007/s10557-006-0634-0. Cardiovasc Drugs Ther. 2006. PMID: 17136490 Review.
-
Malonyl-CoA decarboxylase is a major regulator of myocardial fatty acid oxidation.Curr Hypertens Rep. 2005 Dec;7(6):407-11. doi: 10.1007/s11906-005-0034-z. Curr Hypertens Rep. 2005. PMID: 16386195 Review.
-
Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.J Med Chem. 2006 Mar 9;49(5):1517-25. doi: 10.1021/jm050109n. J Med Chem. 2006. PMID: 16509570
-
Design and synthesis of heterocyclic malonyl-CoA decarboxylase inhibitors.Bioorg Med Chem Lett. 2006 Feb;16(3):695-700. doi: 10.1016/j.bmcl.2005.10.020. Epub 2005 Oct 27. Bioorg Med Chem Lett. 2006. PMID: 16257202
Cited by
-
Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials.Curr Heart Fail Rep. 2018 Jun;15(3):191-197. doi: 10.1007/s11897-018-0386-8. Curr Heart Fail Rep. 2018. PMID: 29707741 Review.
-
Parallel activation of mitochondrial oxidative metabolism with increased cardiac energy expenditure is not dependent on fatty acid oxidation in pigs.J Physiol. 2007 Mar 15;579(Pt 3):811-21. doi: 10.1113/jphysiol.2006.123828. Epub 2006 Dec 21. J Physiol. 2007. PMID: 17185335 Free PMC article.
-
The Contribution of Cardiac Fatty Acid Oxidation to Diabetic Cardiomyopathy Severity.Cells. 2021 Nov 21;10(11):3259. doi: 10.3390/cells10113259. Cells. 2021. PMID: 34831481 Free PMC article. Review.
-
Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy.Br J Pharmacol. 2014 Apr;171(8):2080-90. doi: 10.1111/bph.12475. Br J Pharmacol. 2014. PMID: 24147975 Free PMC article. Review.
-
BRCA1 is a novel regulator of metabolic function in skeletal muscle.J Lipid Res. 2014 Apr;55(4):668-80. doi: 10.1194/jlr.M043851. Epub 2014 Feb 24. J Lipid Res. 2014. PMID: 24565757 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical